Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay

Sudip Bandyopadhyay of Inditrade Capital discusses the positive outlook for the Indian pharma sector following the easing of tariff concerns. He highlights Sun Pharma’s promising developments and Glenmark’s landmark R&D deal. Bandyopadhyay also notes the expected price hike in the steel industry due to increased global demand, while emphasizing company-specific uncertainties like JSW Steel’s Bhushan Steel strategy.

More To Explore

FPIs withdraw Rs 48,056 cr from D-St in Oct

Foreign investors withdrew significant funds from Indian equities in October amid concerns over inflation and crude oil prices. Despite this, there were signs of moderation

October 25, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003